AAP News Vol. 14 No. 12 December 1998, p. 1
© 1998 American Academy of Pediatrics
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

 Previous Article  |  Next Article 

New research, data yield immunization developments: Favorable results spur early end to pneumococcal vaccine trials

An experimental vaccine has proven highly effective against bacterial meningitis and bacteremia caused by Streptococcus pneumoniae.

A three-year Phase III clinical trial involving more than 38,000 California children yielded such favorable results that researchers ended their study ahead of schedule.

"If review by the Food and Drug Administration leads to licensure of this vaccine, children throughout the world will be better off," said Neal A. Halsey, M.D., AAP Committee on Infectious Diseases (COID) chair.